Adaptimmune Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Abingdon, OXF USA
Total Funding:N/A
Industry:Biotech
Founded:2008
Lead Investor(s):N/A

Estimated Revenue & Financials

  • Adaptimmune's estimated annual revenue is currently $64.3M per year.
  • Adaptimmune received $Undisclosed in venture funding in March 2017.
  • Adaptimmune's estimated revenue per employee is $155,000

Employee Data

  • Adaptimmune has 415 Employees.
  • Adaptimmune grew their employee count by 0% last year.
  • Adaptimmune currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$64.3M4150%N/A-N/A
Missing a competitor? Contribute!?
Submit

Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power

415

Number of Employees

$64.3M

Revenue (est)

1

Current Jobs

0%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Adaptimmune News

08/27/2019 - Adaptimmune and Noile-Immune Announce Agreement to ...

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation ...

08/29/2019 - EuroBiotech Report—Celgene-Immatics, AstraZeneca ...

Adaptimmune formed a preclinical research pact. InDex Pharmaceuticals presented phase 2b ulcerative colitis data. And more. — Nick Taylor

08/28/2019 - Adaptimmune and Noile-Immune to Develop SPEAR T-Cell ...

Adaptimmune Therapeutics (NASDAQ:ADAP) announced on Tuesday (August 27) it will be partnering with Japan-based Noile-Immune ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$76.1M423N/AN/A-N/A
#2
$45M4418%N/A-N/A
#3
$94.1M466N/AN/A-N/A
#4
N/A674N/AN/A5/5N/A
#5
$140M8595%N/A-N/A

Adaptimmune Funding

DateAmountRoundLead InvestorsReference
2014-09-26$104.0MUndsiclosedMultipleArticle
2017-03-23$UndisclosedUndisclosedCitigroupArticle

Adaptimmune Executive Hires

DateNameTitleReference
2013-12-02Jonathan KnowlesExecutive ChairmanArticle
2017-10-25Sébastien DesprezVP Communications and Investor RelationsArticle
2018-01-05Paul SteadVP Business DevelopmentArticle